The Filing Desk

Immunome

IMNM · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

IMNM · Last close · November 13, 2026
$18.77
Value Immunome yourself

Immunome's revenue fell 23.2% to $7 million in fiscal 2025. Its operating margin was −3,228.8%, up from −3,382.4% a year earlier. Free cash flow was −$201 million. The diluted share count rose 49.0%.

Immunome Inc. Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0001193125-26-088172 Updated
Revenue
$7M
23.2%
Operating margin
−3,228.8%
153.5 pts
Net income
−$212M
 
Free cash flow
−$201M
 
Return on equity
−52.1%
142.5 pts
Market cap
$2.1B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Immunome does

Immunome is a biotechnology company that develops cancer medicines, with a focus on antibody-drug conjugates, or ADCs, which pair an antibody with a drug that attacks the tumor cells it finds. It has not yet sold a product. Its pipeline has three drugs in testing in people and three earlier ones.

Its lead drug, varegacestat, is a once-daily pill for desmoid tumors, which grow in soft tissue. The company reported positive results from a pivotal Phase 3 trial in December 2025, and says it expects to file for approval in the second quarter of 2026. IM-1021 is an ADC under study in a Phase 1 trial in B-cell lymphoma, and IM-3050 is a radioligand therapy aimed at a protein called FAP.

Immunome designs ADCs against new or little-studied targets and has its own drug payload, HC74. It has a history of losses and says it must raise more money to keep developing its drugs.

Its biggest risks, as it describes them

  • It has a history of losses and may never be profitable.
  • It has not yet filed for approval for a drug or sold one.
  • It must raise a lot more money to advance its drugs.
  • Its ADC platform may not produce a pipeline of drugs.
  • Competitors may develop or sell products faster or more effectively.
From Immunome's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Immunome lost money in fiscal 2025: a net loss of $212 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments4920138217654
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−1,800.3x————
Current ratio5.8x3.1x6.6x4.1x14.7x
Quick ratio5.8x3.1x6.6x4.1x14.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Immunome's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 3 insiders bought $2.3 million of Immunome shares on the open market, and 7 insiders sold $27.5 million, $26.0 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 11, 2026Jack HigginsChief Scientific OfficerSold plan13,200$25.32$334,224Form 4
Aug 12, 2026Isaac BarchasDirectorSold plan11,048$27.25$301,058Form 4
Aug 11, 2026Isaac BarchasDirectorSold plan62,291$26.23$1.6 millionForm 4
Aug 10, 2026Isaac BarchasDirectorSold plan10,125$26.07$263,959Form 4
Aug 7, 2026Isaac BarchasDirectorSold plan15,248$26.06$397,363Form 4
Aug 6, 2026Isaac BarchasDirectorSold plan20,840$26.06$543,090Form 4
Aug 4, 2026Kinney HornChief Business OfficerSold plan90,616$25.09$2.3 millionForm 4
Jul 7, 2026Isaac BarchasDirectorSold plan16,906$24.20$409,125Form 4
Jul 7, 2026Kinney HornChief Business OfficerSold plan1,092$25.00$27,300Form 4
Jul 6, 2026Isaac BarchasDirectorSold plan83,094$24.11$2.0 millionForm 4
Jul 2, 2026Isaac BarchasDirectorSold plan100,000$22.59$2.3 millionForm 4
Jul 2, 2026Robert LechleiderChief Medical OfficerSold plan55,000$22.62$1.2 millionForm 4
The latest 12 of 30 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40—−1,340.3%−2,913.4%
Altman Z''−0.03−7.7713.87
Accruals ratio−115.0%−93.7%−4.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets—FailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Immunome side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
ImmunomeFY25−23.2%−3,228.8%−2,890.1%———
Ovid TherapeuticsFY251,181.3%−585.2%−528.6%———Compare
Xenon PharmaceuticalsFY25—−4,974.3%−3,732.2%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
PrecigenFY25146.7%−1,141.1%−927.6%——2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue————1497
Revenue growth—————−35.5%−23.2%
Gross profit———————
Research and development98142323130177
Operating income−10−12−25−37−110−306−224
Net income−10−18−25−37−107−293−212
Diluted EPS (US$)−9.55−5.26−2.14−3.09−5.38−5.00−2.43
Diluted shares (millions)131212205987
Cash flow
Cash from operations−10−12−18−29−8−111−191
Capital expenditure01001710
Free cash flow−10−13−18−29−8−118−201
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation013561626
Balance sheet at fiscal year end
Cash and short-term investments2404920138217654
Debt incl. finance leases—0—————
Total assets5445824148240683
Total liabilities23107295949
Shareholders' equity−36414817120181634
Margins and ratios
Gross margin———————
Operating margin————−781.4%−3,382.4%−3,228.8%
Net margin————−761.9%−3,240.4%−3,060.0%
Free cash flow margin————−59.9%−1,304.8%−2,890.1%
Rule of 40 (growth + FCF margin)—————−1,340.3%−2,913.4%
Return on capital———————
Return on equity—−624.2%−55.2%−113.8%−156.4%−194.6%−52.1%
Return on assets—−72.0%−48.2%−90.0%−123.8%−150.7%−46.0%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Immunome's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Immunome.